Organization | Skåne University Hospital

Skåne University Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2020

NCT04332822

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Alternative names

Department of Endocrinology, Skåne University Hospital, Malmö, Sweden | Department of Internal Medicine, Skåne University Hospital, Malmö | Department of Oncology, Skåne University Hospital

Active Ingredients

Drugs in Phase 3 Trials (6)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

polatuzumab vedotin (Polivy) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (2 trials)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (1)

acalabrutinib (calquence) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 7